Skip to main content

Table 5 Results of pulmonary function tests and respiratory muscle strength among COVID-19 patients between glucocorticoid group and the regular groups

From: Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Parameter

All patients (n=57)

GC group (n=16)

Regular group (n=41)

p Value

FVC (% of predicted)

100.96 (15.93)

97.25 (18.69)

102.40 (14.72)

0.414

FEV1 (% of predicted)

97.89 (14.91)

94.35 (15.40)

99.27 (14.68)

0.279

FEV1 / FVC (%)

81.22 (6.13)

80.74 (4.68)

81.40 (6.65)

0.804

TLC (% of predicted)

93.94 (12.75)

90.15 (16.01)

95.45 (11.06)

0.323

RV (% of predicted)

90.68 (28.08)

85.49 (19.01)

92.76 (30.95)

0.593

DLCO (% of predicted

78.38 (13.59)

74.67 (14.37)

79.78 (13.20)

0.657

Raw (% of predicted)

105.38 (31.38)

96.02 (25.81)

109.22 (32.93)

0.214

R5 (% of predicted)

126.64 (29.45)

119.66 (30.62)

129.37 (28.91)

0.127

R20 (% of predicted)

132.76 (30.95)

123.51 (31.99)

136.37 (30.15)

0.106

Pimax (% of predicted)

76.16 (24.28)

85.21 (26.54)

72.53 (22.65)

0.059

Pemax (% of predicted)

102.73 (32.68)

104.22 (28.03)

102.14 (34.68)

0.479

  1. Values given as % predicted, unless otherwise indicated
  2. GC glucocorticoid